Stay updated on Pembrolizumab Combo with Canakinumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo with Canakinumab in NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab Combo with Canakinumab in NSCLC Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe record history now shows a new revision (v3.5.3) replacing the previous v3.5.2. It represents an update to the study record in the history log.SummaryDifference0.0%

- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedAdded Revision: v3.5.2 to the history and removed Revision: v3.5.0.SummaryDifference0.0%

- Check57 days agoChange DetectedNew revision entry v3.5.0 added to the history. The v3.4.3 entry was removed.SummaryDifference0.0%

- Check64 days agoChange DetectedFooter revision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check71 days agoChange DetectedThe trial status is updated to Terminated with primary results showing no benefit from canakinumab. The previous Active, not recruiting status has been removed.SummaryDifference0.2%

- Check92 days agoChange DetectedThe latest version adds a Contacts/Locations section and a Study Status update to the record. These additions improve access to study contact information and the current recruitment status.SummaryDifference0.5%

Stay in the know with updates to Pembrolizumab Combo with Canakinumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo with Canakinumab in NSCLC Clinical Trial page.